FDA agreed, and later patients were only given LRM on Day 0 and Day 7 of a 28 day trial (theoretically) using a monoclonal antibody whose half-life is 10 days. Why patients were not dosed on day 14 or 21 certainly is confusing.
The rest of the history we know quite well, but it makes me smile to think back when Dr. S was asking the right questions at the right time. It can be argued who was listening and who was not but at least we had Dr. S asking questions out loud.
https://pubmed.ncbi.nlm.nih.gov/39353749/